ABSTRACT -Atelocollagen (AC), a biomaterial with low antigenicity and high bioaffinity, has been widely used in implantable materials in clinical practice. Preclinical studies have demonstrated that AC is a potential drug carrier for local and systemic delivery of cytokines, growth factors, plasmid DNA, small interfering RNA, and microRNA. AC is also believed to have low systemic toxicity on the basis of the safety of implant usage; however, this is not enough determined. Therefore, we performed whole genome expression profiling in mouse liver after systemic administration of AC or the cationic liposome carrier DOTAP/cholesterol (LP) and compared the changes of gene expressions associated with hepatotoxicity. Microarray analysis revealed that systemic LP administration significantly increased expression of toxicity-related genes, i.e., those for lipocalin-2, cyclin-dependent kinase inhibitor 1A, serum amyloid A isoforms, chemokine ligands, and granzyme B. Alternatively, AC administration did not alter the expression of any of these genes. Further gene ontology (GO) enrichment analysis highlighted the characteristic annotations extracted from genes upregulated after LP administration, and most of them were related to toxicity annotations such as immune response, inflammatory response, and apoptosis induction. In contrast, GO enrichment analysis of genes induced after AC administration revealed that only three annotations, all of which were unrelated to toxicity. These findings indicate that AC is potentially far less hepatotoxic than LP after systemic administration, suggesting that AC may be an excellent biomaterial for nontoxic drug delivery system carriers.
INTRODUCTION
The efficiency of drug delivery systems (DDSs) to target tissues and cells is one of the critical issues determining their successful clinical application. DDS improves the drug release profile, distribution, and duration, resulting in enhanced drug effects and diminished adverse effects. At present, liposomes appear to be the most promising DDS carriers for clinical applications, and therefore, many researchers and pharmaceutical companies have developed liposome-based DDS carriers. Liposomes can form complexes with a multitude of compounds, such as plasmid DNA, small interfering RNA (siRNA), oligonucleotides, peptides, anticancer compounds, antibodies, and adjuvants for radiotherapy, chemotherapy, and antibiotics. Among these liposome-based DDS carriers, cationic liposomes are the most popular and successful for delivering these compounds in vivo and in vitro (Simberg et al., 1984) . The efficacy of cationic liposomes as DDS carriers is gradually improving, but their safety remains controversial (Lonez et al., 2008; Sakurai et al., 2007) . To develop a nontoxic DDS carrier, we have examined a collagen derivative as an alternative carrier.
Atelocollagen (AC), a form of collagen without the terminal peptides, has been widely used for more than 30 years as a topical hemostatic agent and in wound dressings (Miller et al., 1964; Chvapil et al., 1973) . It has extremely low antigenicity because of the elimination of endogenous antigenic regions and exogenous pathogens by proteolytic processing. It has also been extensively used as a scaffold for the three-dimensional culture of many cell types, thus demonstrating high bioaffinity with multiple tissues. AC is known to interact with numerous biomolecules with varying affinities, which plays important roles in hemostasis, cell differentiation, homeostasis, and osteogenesis (Di-Lullo et al., 2002; Yamazaki et al., 2010) . This property allows AC to transport miscellaneous biomolecules and compounds and release them to target tissues.
During the last decade, studies have shown that AC is an efficient carrier of toxoid vaccines (Higaki et al., 2001) , cytokines (interferon, bFGF, G-CSF, BMP-2) (Maeda et al., 1996; Hosokawa et al., 2000; Fujimura et al., 1995) , plasmid DNA (Ochiya et al., 1999; Sano et al., 2003) , siRNA (Honma et al., 2008) , microRNA (Tazawa et al., 2007) , and antisense oligonucleotides (Nakazawa et al., 2007) . AC may function as an efficient DDS carrier by binding and forming a complex with compounds through intermolecular forces, and thereby protecting these compounds from degradation and/or releasing them slowly in target tissues or cells. Consequently, the pharmaceutical effects of drugs are enhanced or sustained. AC also enhances membrane permeability, e.g., complexes of AC and plasmid DNA can be introduced into cells both in vitro and in vivo after local administration . Several research groups have successfully introduced siRNA or miRNA into cells by forming a complex with AC and demonstrated therapeutic effects in animal models of cancer, inflammation, or muscular dystrophy (Takei et al., 2006; Sasaki et al., 2010; Kinouchi et al., 2008) using the AC-based in vivo siRNA/miRNA transfection reagent AteloGene ® , and clinical studies of therapeutic compounds using AC as a DDS carrier are in progress.
Although details of AC toxicity after intravenous injection in animals has not been reported, Gomes et al. (1991) reported preliminary data on the toxicity of collagens extracted from the skin of rats, guinea pigs, and rabbits and tail of rats after intravenous infusion in rabbits. Infusion of these collagens at 2 mg/kg caused respiratory distress, convulsions, and final death, and these toxic responses appeared to stem from occlusion of the lung and liver microcirculation by collagen-mediated platelet aggregation (Gomes et al., 1991) .
To assess the systemic toxicity of AC, we performed a microarray-based whole genome expression profiling in mouse liver tissue. A DNA microarray can profile expression of the entire genome in most organisms; therefore, this multiplex technology is widely employed in pharmaceutical clinical research, food safety inspection, and in vitro diagnostics (Hardiman, 2008) . In toxicogenomics, this technique is considered a powerful tool that enables high-sensitivity and high-throughput analysis of hepatotoxicity (Heinloth et al., 2004; Steiner et al., 2004) , nephrotoxicity (Amin et al., 2004; Thukral et al., 2005) , and genotoxicity (Ellinger-Ziegelbauer et al., 2009 ).
Here we examined the toxicity of AC and cationic liposomes 24 hr after systemic administration. We focused on hepatotoxicity because the liver is susceptible to toxicity caused by many pharmaceutical compounds and environmental chemicals. Furthermore, studies have already demonstrated the promising DDS carrier potential of AC for targeted therapy against cancer cells in liver (Kawata et al., 2008) . Cationic liposomes have also been used to target DNA to liver epithelial cells (McLean et al., 1997) . Therefore, we systemically administered these DDS carriers at the manufacturer's recommended concentrations in separate groups of mice. The microarray-based whole genome expression profiles showed that AC had considerably lower hepatotoxicity than cationic liposomes, suggesting that AC is a promising low-toxicity DDS carrier for clinical use.
MATERIALS AND METHODS

Experimental animals
Eight-week-old male C57BL/6 mice were obtained from Japan SLC Inc. and acclimated for 1 week under standard conditions at the animal facility of Koken Research Institute. All animal experimental protocols were approved by our institute's committee for ethics in animal experimentation.
AC preparation
We used AteloGene ® (Koken, Tokyo, Japan), a highly purified type I AC dissolved in neutral pH buffer and prepared from the bovine dermis by protease treatment, precipitation, and filtration, resulting in elimination of terminal peptides of collagen and various contaminants by which immune responses can be elicited.
We prepared AC formulations according to the AteloGene instruction manual but without siRNA. In brief, 10 × siRNA buffer from the AteloGene kit was diluted to 1 × concentration in sterilized water. The 1 × siRNA buffer without siRNA was gently poured into the AC stock solution and slowly mixed by rotation at 4°C. The mixture was centrifuged at 12,000 rpm for 5 min at 4°C, drawn into a disposable syringe, and placed on ice until use. The final concentration of AteloGene was determined according to our AC viscosity data (Supplemental Fig. 1 ). AC concentration was selected such that the final solution was less viscous than mouse whole blood, resulting in the suppression of collagen-mediated platelet aggregation. The use of AC in mice has also been described in previ-ous studies (Minakuchi et al., 2004; Sano et al., 2003) .
DOTAP/Cholesterol
A cationic liposome formulation for systemic administration, In vivo MegaFectin, was purchased from MP biomedicals (Santa Ana, CA, USA). This formulation consists of N- [1-(2,3-dioleoyloxy) propyl]-N,N,N-trimethylammonium methyl sulfate (DOTAP) and cholesterol. Administration without any nucleic acids or enhancer reagents was performed according to the manufacturer's instructions. In brief, 100 μl of HEPES buffer (20 mM, pH 7.4) without nucleic acids was added dropwise into the same volume of rehydrated liposome solution, drawn into a disposable syringe, and stored at room temperature until use.
Systemic administration
Using 1 ml, 26 G × ½ syringes (Terumo, Tokyo, Japan), 200 μl of AC, cationic liposome (DOTAP/cholesterol; LP), or nuclease-free Dulbecco's PBS (Ambion, Austin, TX, USA) was infused via the tail vein (n = 4 mice per treatment group) at a rate of 200 μl/15 sec. After 24 hr, the mice were sacrificed by cervical dislocation to prevent the effect of an anesthetic drug on hepatic gene expression, and mouse livers were immediately harvested and soaked in RNAlater (Ambion) 4°C for 12 hr. Treated liver tissues were stored at -20°C until use.
Isolation of mRNA, reverse transcription, and hybridization
Total RNA was extracted from homogenized livers using the RNeasy Mini Kit (Qiagen, Venlo, Netherlands). The quality of total RNA obtained was calculated by the ratio of absorbance (OD 260 nm /OD 280 nm = 1.8-2.0 and OD 260 nm /OD 280 nm > 2.0). In addition, appropriately shaped RNA bands, absence of degradation products, and a 28S/18S rRNA ratio of at least 2.0 were confirmed on electrophoresis to ensure the RNA quality. Then, 250 ng of total RNA from each sample was reverse transcribed to cDNA and hybridized with probes on a Whole Mouse Genome Microarray chip G4122F using the Low RNA Fluorescent Linear Amplification Kit Plus, RNA SpikeIn Kit, and Gene Expression Hybridization Kit (Agilent Technologies, Santa Clara, CA, USA).
Microarray analysis
Mouse whole genome microarray analysis was performed using the 4 × 44K Oligo Microarray System (Agilent Technologies). Isolated total RNA was tagged with Cy3-labeled cRNA and prepared for microarray analysis using the One Color RNA Spike-In Kit and Gene Expression Hybridization Kit.
Data analysis was performed using GeneSpring GX (Agilent Technologies) at DNA Chip Research Inc. (Kanagawa, Japan). Genome-wide gene expression data from AC-and LP-treated livers were expressed as fold changes compared to the median expression values in PBS-treated livers as the background levels. Each set of gene expression data consisted of averaged data from at least 2 of 4 mice per treatment group. If a certain gene expression data included more than 3 invalid spots, such as improper shape and/or undetectable, the data was excluded.
Gene ontology (GO) enrichment analysis
GO enrichment analysis on microarray data was performed using GeneSpring GX. First, we selected upreg- ulated (expression changes ≥ 2.0-fold, and P < 0.05) or downregulated (expression changes ≤ 0.5-fold, and P < 0.05) genes. The data were then processed with Fisher's exact test and multiple test correction to identify significant overrepresentation of GO annotations belonging to biological processes [GO:0008150 (including 33,258 genes and 89,073 annotations)].
RESULTS
Whole genome expression profile
We performed whole genome expression analysis of mouse liver tissues 24 hr after tail vein injection of AC or LP. We compared the test DDS carrier AC to LP (a formulation of DOTAP/cholesterol) because LP is one of the most popular in vivo DDS carrier used for nucleic acids (Fig. 1) . Control mice were injected with Dulbecco's PBS as sham treatment for analysis of baseline expression profiles. Figure 1 shows the changes in whole genome expression (available 23,747 spots / total 41,174 spots) after the 2 carrier treatments. The expression levels of 336 spots were increased by 2.0-fold and more relative to baseline expression (median expression of the PBS-treated control group) 24 hr after AC administration, while 805 spots were upregulated by LP administration. The expression levels of 22 and 255 spots were decreased by 0.5-fold and less relative to baseline expression after AC and LP administration, respectively. The top 50 upregulated genes are listed in Table 1A , where genes marked with dagger ( †) are annotated with at least one any of toxicity related terms, such as inflammatory response (GO:0006954), apoptosis induction (GO:0006915), or response to the DNA damage stimulus (GO:0006974). Toxicity-related genes upregulated 24 hr after AC administration included only 3 genes (Alox5; Arachidonate 5-lipoxygenase, Gadd45g; Growth arrest and DNA-damage-inducible protein gamma, and Smad3; Mothers against decapentaple- 6.60 ± 10.38 *Relative expression level (PBS treatment = 1.00) ± S.D. † Genes annotated with at least one toxicity related term (e.g., response to toxicity, such as inflammatory response (GO:0006954), apoptosis (GO:0006915), or response to DNA damage stimulus (GO:0006974)). gic homolog 3). In addition, a large proportion of upregulated genes after AC administration were also enhanced by LP administration to the same level. In contrast, genes significantly upregulated after LP administration included many toxicity-related genes (genes with † in left-side of Table 1A ) and unchanged by AC. Exceptionally, metallothionein 1 (Mt1), Cyclin-dependent kinase 5 activator 2 (Cdk5r2), Poly(rC)-binding protein 1 (Pcbp1), Eukaryotic initiation factor 4A-I (Eif4a1), Endothelial cell-specific molecule 1 (Esm1), and Trefoil factor 3 (Tff3) were also upregulated after AC, but most of them were not toxicity related genes (highlighted in underline in Table 1A) .
Among the upregulated genes annotated with toxicities, we prepared a list of genes that were strongly upregulated only after LP administration (Table 1B) . These genes included those for key factors of apoptotic and inflammatory factors such as lipocalin 2 (Lpc2, a known innate immune responsive gene), p21/cyclin-dependent kinase inhibitor 1A (Cdkn1A), serum amyloid A isoforms 1-3 (Saa1, Saa2, and Saa3), chemokine ligands (Ccl7, Ccl2 and Cxcl9), and granzymes (Gzmb and Gzma). Among these genes, the expression Lpc2 level was significantly elevated after LP administration (Table 1B) . Figure 2 shows expression data on apoptosis-related genes (available 826 spots annotated with GO:0006915) in heatmap selected from the whole genome expression data in Fig. 1 (Fig. 2) . Altered expression of these genes was significantly less common after AC administration than after LP administration. The expression levels of 8 spots were upregulated by at least 2.0-fold relative to baseline expression 24 hr after AC administration, while 38 spots were upregulated by at least 2.0-fold after LP administration. The expression levels of 1 and 5 spots were downregulated to 0.5-fold and less relative to baseline expression 24 hr after AC and LP administration, respectively. As shown in Fig. 2(B) , expression of several major apoptosis inducers, including p21/cyclin-dependent kinase inhibitor 1A (Cdkn1A, AC: 1.0-fold, LP: 21.9-fold), granzyme B (Gzmb, AC: 1.0-fold, LP: 4.4-fold), chemokine CC motif ligand 2 (Ccl2, AC: 0.8-fold, LP: 6.7-fold), Pycard (AC: 1.2-fold, LP: 4.0-fold), Scotin (AC: 0.9-fold, LP: 4.0-fold), and Fas (AC: 1.2-fold, LP: 2.0-fold) was strongly altered after LP administration, while their expression did not change substantially after AC administration (0.8-fold to 1.2-fold).
Expression profile of apoptosis-related genes
Expression profile of chemical stimulation response-related genes
Figure 3(A) illustrates changes in expression of 380 genes related to response to chemical stimuli (GO:0042221), which includes genes for both immune response (GO: 006955) and inflammatory response (GO: 006954) such as those for chemokine ligands and receptors (Cxcl9, Ccl6, Ccr2, Cc.4, Ccl19, and Ccl5). Altered expression of these chemical stimulation response-related genes was significantly less common after AC administration than after LP administration. The expression levels of 6 spots were upregulated by 2.0-fold and more than relative to baseline expression 24 hr after AC administration, while 27 spots were upregulated by at least 2.0-fold 24 hr after LP administration. On the other hand, the expression levels 5 spots were downregulated to 0.5-fold and less relative to baseline expression 24 hr after LP administration, while none of these chemical stimulation response-related genes were downregulated after AC administration.
As shown in Fig. 3(B) , expression of many chemokine receptors and ligands, including Ccr2 (4.0-fold), Ccl4 (5.0-fold), and Ccl2 (6.8-fold), was upregulated after LP administration. On the other hand, the expression of dual oxidase 1 (Duox1) and viral interferon regulatory factor 4 (V1rf4) was enhanced only after AC administration. These 2 genes are known to be associated with olfaction or chemoreception, but their correlation with immune and/or inflammatory response is unclear. Viral interferon regulatory factor 1 (V1rf1), colony-stimulating factor 3 receptor (Csf3r), leucine rich repeat containing 38 (Lrrc38), and guanylate cyclase 2C (Gucy2c) were moderately enhanced after AC administration. Their expression was also upregulated after LP administration. Exceptionally, expression of an important apoptosis factor, pro-apoptotic Bcl-2 antagonist/killer (Bak1) was moderately enhanced after AC and LP administration. 
Data mining for up-or downregulated genes
For further processing based on Gene Ontology, we plotted all the processed expression data (AC: 23,664 spots, LP: 23,999 spots) on volcano plots (Fig. 4) and sorted genes as upregulated or downregulated according to their respective thresholds (expression changes ≥ 2.0 or ≤ 0.5 fold, and P < 0.05, shown as red points in Fig. 4) . The horizontal axes represented the logarithmic fold changes in gene expression. The vertical axes represented the logarithmic reciprocal of the P value.
According to the preceding criteria, 212 and 653 spots were identified as upregulated after AC and LP administration, respectively. Although 129 spots were identified as downregulated after LP administration, no spots were identified as downregulated after AC administration. The magnitude of changes in gene expression induced by LP administration was generally much higher than that induced by AC administration as indicated by the wide scatter of points to the right and left of the horizontal axis (Fig. 4) . Thus, LP administration had a much greater effect on hepatic gene expression as indicated by both the number of altered genes and the magnitude of individual changes. 
GO enrichment analysis of up-or downregulated genes
To extract the characteristic GO annotations belonging to biological processes (GO:0008150) from upregulated genes, we performed GO enrichment analysis of upregulated genes (indicated by the red points in right side of Fig. 4) . Table 2 lists the characteristic annotations (P < 0.001) for significantly upregulated genes (expression changes ≥ 2.0 and P < 0.05) after AC or LP administration. Many toxicity-related annotations were related to LP administration with very high probability. On the other hand, only 3 annotations (protein biosynthesis, macromolecule biosynthesis, and cellular biosynthesis) were related to AC administration. Significant differences were observed in their probabilities (P = 0.1 × 10 −5 to 5.0 × 10 −4 ); however, these annotations were not related to toxicity. These results indicated that AC was significantly less hepatotoxic than LP.
We then characterized downregulated genes (expression changes ≤ 0.5-fold and P < 0.05) by GO enrichment analysis (P < 0.01) ( Table 3 ). As shown in Fig. 4 , no genes were identified as downregulated after AC administration. Table 1B shows that the genes downregulated after LP administration were characterized by various metabolism-related GO annotations with moderate probability (P = 1.00 × 10 4 to 1.00 × 10 2 ). These results suggest that repeated LP administration can cause depression of liver metabolism, resulting in chronic hepatic dysfunction.
DISCUSSION
We performed DNA microarray-based whole genome expression profiling using mouse livers harvested 24 hr after tail vein injection of AC, LP, or Dulbecco's PBS. Expression of a large number of toxicity-related genes was strongly upregulated after LP administration (Table  1A) . These included apoptosis-and inflammation-related genes (Gzmb, Gzma, Ccl7, Ccl2, Cxcl9, Cdkn1A, Saa1, Saa2, and Saa3, and Lpc2; Table 1B ). In contrast, AC induced the upregulation of fewer than half as many genes, and most of these genes were not associated with cell toxicity.
Gzma and Gzmb are known secretion-type cell death signals synthesized by cytotoxic T lymphocytes and natural killer cells and can induce programmed cell death or apoptosis of target cells . Furthermore, chemokine ligands such as Ccl7, Ccl2, and Cxcl9 are involved in recruiting leukocytes to initiate local inflammation (Fernandez and Lolis, 2002) . Upregulation of both leukocyte attractants (chemokine ligands) and leucocyte products (Granzymes) strongly suggests that LP can induce hepatocellular damage, resulting in the invasion of leukocytes, including cytotoxic T cells, into liver tissues.
Serum amyloid A isoforms (Saa1, Saa2, and Saa3) and Cdkn1a are p53-induced genes (PIGs) known to facilitate apoptosis progression (Polyak et al., 1997) . Saa1, also known as PIG4, is a major acute phase protein that is highly expressed in response to inflammatory cytokines such as Il1, Il6, and TNFs during inflammation and tissue injury (Quinton et al., 2009) . In this study, we observed the upregulation of expression of several PIGs (Ckdn1a, Saa1, Saa2, and Saa3) after LP administration, while the expression of faster apoptosis inducers, such as p53, interferons, interleukins (Il1 and Il6), and TNFs, remained unchanged or undetectable. The reason for this contradictory observation may be that the upregulation of these transient apoptosis inducers have been missed at 24 hr after injection because expression have already returned to baseline. According to Ito et al. (2009) , the serum TNF-α level was immediately increased after intravenous injection of LP, but it returned to baseline after 3 hr. The serum level of ALT, an indicator of hepatocyte destruction, remained unchanged until 12 hr after LP administration, but it increased thereafter, peaking at 24 hr before declining to baseline. Therefore, harvesting at 24 hr is the time at which the subsequent reaction caused by the first cytokine response to LP occurs.
We performed a variable subset selection from the whole genome expression data based on GO enrichment analysis (Tables 2 and 3) that again revealed induction of multiple toxicity-related genes after LP administration but few toxicity-related genes after AC administration. Many toxicity-related annotations were related to LP administration with a very high probability (P < 1.00 × 10 5 to 1.00 × 10 55 ). We did observed greater than 2.0-fold upregulation of a few toxicity-related genes after AC administration, including Gadd45ab, Fasl, and Nfkb, but GO enrichment analysis indicated no toxicity-related annotations associated with AC administration (Table 2) . Therefore, systemic AC administration was not statistically associated with toxicity.
An investigation of AC with siRNA/miRNA is a very interesting issue, but administration of AC and LP was executed without siRNA, miRNA, or any other compounds for this study. This study tested DDS carriers (AC and LP) without siRNA, miRNA, or any other compounds, thus we did not assess the toxicity of carrier-drug combinations. Small double-stranded RNA, such as siRNA, cause an immune response mediated by tolllike receptor 3 (TLR-3) (Cho et al., 2009) . AC inhibits siRNA degradation by forming an AC-siRNA complex (Minakuchi et al., 2004) . Thus, AC is expected to prevent contact between siRNA and TLR-3. In addition, it is also conceivable that complex formation may inhibit toxicity by inhibiting non-specific interactions between therapeutic and non-target molecules. To develop the safety of an AC-based DDS carrier, it is necessary to investigate how AC-nucleic acid complexes affect expression of toxicityrelated genes in humans.
In this study, we demonstrated the low hepatotoxicity of systemic AC administration. Although the mechanism by which AC affects gene expression in other organs remains unknown, low hepatotoxicity suggests that AC is a potentially safe drug carrier. Therefore, more detailed characterizations of AC may facilitate the development of a safe and efficient drug delivery carrier. 
